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Glioblastoma multiforme (GBM) are resistant to TNFa-induced apoptosis and blockade of TNFa-induced NF-jB activation
sensitizes glioma cells to apoptosis. As Casein kinase-2 (CK2) induces aberrant NF-jB activation and as we observed elevated
CK2levelsinGBMtumors,weinvestigated thepotentialofCK2inhibitors(CK2-Is)-DRBandApigenininsensitizing gliomacells
toTNFa-inducedapoptosis.CK2-IsandCK2smallinterferingRNA(siRNA)reducedgliomacellviability,inhibitedTNFa-mediated
NF-jB activation, and sensitized cell to TNFa-induced apoptosis. Importantly, CK2-Is activated p53 function in wild-type but not
in p53 mutant cells. Activation of p53 function involved its increased transcriptional activation, DNA-binding ability, increased
expression of p53 target genes associated with cell cycle progression and apoptosis. Moreover, CK2-Is decreased telomerase
activityandincreasedsenescence inap53-dependentmanner.Apoptoticgene proﬁlingindicatedthatCK2-Isdifferentiallyaffect
p53andTNFatargets inp53wild-typeandmutantglioma cells.CK2-IdecreasedMDM2-p53 associationandp53ubiquitination to
enhance p53 levels. Interestingly, CK2-Is downregulated SIRT1 activity and over-expression of SIRT1 decreased p53
transcriptional activity and rescued cells from CK2-I-induced apoptosis. This ability of CK2-Is to sensitize glioma to
TNFa-induced death via multiple mechanisms involving abrogation of NF-jB activation, reactivation of wild-type p53 function
and SIRT1 inhibition warrants investigation.
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Despite its ability to induce apoptosis, several tumors are
resistant to TNFa-mediated apoptosis.
1 This resistance has
been attributed to TNFa-mediated NF-kB activation as
blockade of NF-kB sensitizes cells to TNFa-induced cell
death.
2,3 Some anti-cancer chemotherapeutic drugs in
combination with TNFa can kill resistant tumor cells.
4
Glioblastoma multiforme (GBM) – the most aggressive
malignant brain tumor, is largely resistant to current
therapeutic regimens. We have reported that organoselenium
EbselensensitizesgliomacellstoTNFa-inducedapoptosisby
abrogating NF-kB activation.
5
Casein kinase-2 (CK2)– a protein kinase important for cell
survival and resistance to apoptosis,
6 is over-expressed in
several malignancies.
7 CK2 negatively regulates caspase
activity
8 and CK2 inhibitors (CK2-Is) increase the susceptibility
of cancer cells to chemotherapeutic agents or apoptotic stimuli.
9
CK2 inhibitor, DRB, sensitizes tumor cells to TRAIL (TNFa-
related apoptosis inducing ligand)-induced apoptosis.
10 CK2
inhibitor, Apigenin, inhibits NF-kB activation in breast cancer cell
lines
11 and DRB enhances Apo2L/TRAIL-induced glioma cell
death.
12 CK2-I blocks TNFa-induced p65 phosphorylation
13 and
reduces constitutive NF-kB activity in breast cancer cells.
14
TNFa-activatedNF-kBrepressesp53transcriptional activityand
vice versa.
15 Most GBMs harbor p53 mutations, which are
considered critical in GBM development
16 and p53 rescue
compounds induce p53-dependent growth arrest and sensitizes
glioma cells to Apo2L/TRAIL-induced apoptosis.
17
SIRT1 an NADþ (nicotinamide adenine dinucleotide)-
dependent deacetylase, known to decrease transcriptional
activity of p53,
18 is a component of CK2-regulated anti-apoptotic
network.
19 Silencing of SIRT1 enhances sensitivity of glioblas-
toma to radiotherapy.
20 Accordingly, we investigated whether
CK2-Is could sensitize glioma cells to TNFa-induced apoptosis
through regulation of molecules associated with cell survival and
resistance to apoptosis such as NF-kB, p53 and SIRT1.
Results
Elevated CK2 levels in glioblastoma biopsy
samples. Though the ability of CK2 inhibitor to regulate
DNA damage repair response and induce antitumor activity
in a mouse xenograft model of human glioblastoma has been
reported,
21 nothing is known about the status of CK2 in
human glioma samples. We therefore investigated the status
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www.nature.com/cddisof CK2 in GBM tumors. Immunohistochemistry (IHC)
revealed an elevated expression of CK2a in GBM tumors
as compared with adjacent normal tissues (Figure 1a).
Western blot analysis also conﬁrmed an increased CK2a
expression in glioma tissue as compared with the
surrounding non-neoplastic tissue (Figure 1b).
Figure 1 CK2 inhibition sensitizes glioma cells to TNFa-induced apoptosis. (a) CK2 immuno-localization in glioma tumor samples. Cryosections of glioma and adjacent
normal tissues were immunostained for CK2a as described in Materials and Methods. Images were taken at 40  magniﬁcation. (b) Western blot analysis demonstrating
elevated CK2a expression in GBM tumor as compared with surrounding non-neoplastic tissue. The ﬁgure shows blots from ﬁve independent tumor samples with identical
results. (c) Viability of glioma cells treated with CK2-Is in the presence and absence of TNFa was determined by MTS assay. The graphs represent the viable glioma cells,
percentage of control, upon treatment with 50ng/ml TNFa either alone or in combination with different concentrations of DRB or Apigenin for 24h. (d) The graphs represent
percentage of TUNEL-positive glioma cells upon treatment with either DRB/Api or TNFa or both, as counted from multiple ﬁelds. (e) siRNA-mediated knockdown of CK2
decreasesgliomacellviabilityasdeterminedbyMTSassay.Thegraphrepresentstheviablegliomacells,percentageofcontrol,transfectedwithCK2a/bsiRNAwhentreated
withTNFafor24h.InsetshowstheknockdownefﬁciencyofCK2asiRNA.(f)Increaseincaspase-3activityingliomacellstreatedwithCK2-IsorTNFaorboth,asdetermined
by caspase-3 activity assay. Values (c–f) represent the means ±S.E.M. from three independent experiments. *Denotes signiﬁcant change from control (Po0.05)
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Cell Death and DiseaseCK2 regulates glioma cell viability and confers
resistance to TNFa–induced apoptosis. As CK2 levels
were elevated in GBM samples, we investigated its role in
glioma cell survival and resistance to apoptosis. Although
treatment with 20mM of DRB had no effect on cell viability,
B20–30% reduction in viability was observed upon
treatment with 40, 60 and 80mM of DRB, respectively
(Figure 1c). Although treatment with TNFa alone had no
effect on viability of glioma cells, co-treatment with 20, 40, 60
and 80mM of DRB resulted in B30–65% decrease in
viability, as compared with control (Figure 1c). Similarly,
Apigenin also affected cell viability (Figure 1c). Thus, both
DRB and Apigenin sensitized glioma cells to TNFa-induced
apoptosis. We chose 40mM concentration of DRB and
Apigenin for subsequent treatments. To further conﬁrm
CK2-I-mediated apoptotic death, TUNEL assay was
performed (Figure 1d). The 15–25% increase in TUNEL-
positive cells observed upon DRB and Apigenin treatment
was further elevated to B 50–60% when DRB or Apigenin
was co-administered with TNFa (Figure 1d). To further
conﬁrm the involvement of CK2 in glioma cell survival,
viability of cells transfected with small interfering RNAs
(siRNAs) against a and b subunit of CK2, both in presence
and absence of TNFa was determined. The 20–25%
decrease in cell viability observed upon siRNA-mediated
knock-down of CK2 a/b subunits was further elevated to
30–40% in the presence of TNFa (Figure 1e).
The signiﬁcant 1.3, 1.5 and 1.7-fold increase in caspase-3
activity observed in U87MG, A172 and T98G cells upon
treatment with DRB, respectively, was further elevated to 2.9,
3.2 and 4.0-fold in the presence of TNFa. Similar activation of
caspase-3 was also observed in cells treated with Apigenin
either alone or in combination with TNFa (Figure 1f).
CK2-I-mediated apoptosis does not involve caspase-8
activation. Interaction of Fas with FADD recruits
procaspase-8 that induces subsequent caspase-8 and
caspase-3 activation leading to apoptosis. Although CK2
inhibition is known to trigger apoptosis through FADD and
caspase-8,
22 CK2-Is had no effect on FAS or FADD
expression (Figure 2a) or caspase-8 activity (Figure 2b) in
glioma cells, both in presence and absence of TNFa.T o
further conﬁrm the role of caspase-8, the viability of cells
treated with different combinations of TNFa and CK2-I in the
presence and absence of caspase-8 inhibitor was
determined. CK2-I-mediated decrease in cell viability
remained unaffected in the presence of caspase-8 inhibitor
(Figure 2c). This ruled out the possible involvement of
caspase-8 in CK2-I-induced apoptosis.
CK2-Is abrogate TNFa induced NF-jB activity in glioma
cells. CK2 is known to regulate NF-kB through regulation of
IKK.
23 Treatment with CK2 inhibitors decreased TNFa-
induced pIkKa/b level in glioma cells (Figure 2d). This
decrease was concomitant with increase in IkBa and
decrease in NF-kB levels (Figure 2d). As CK2-I prevents
NF-kB activation,
11 we investigated whether CK2-Is increase
sensitivity to TNFa-induced apoptosis through inhibition of
NF-kB activity. Transfection of glioma cells with NF-kB
luciferase reporter followed by TNFa treatment demonstrated
B9–11-fold increase in luciferase activity over the vector
control (Figure 2e). Although treatment with DRB or Apigenin
alone had no signiﬁcant effect on NF-kB activity, CK2-Is
reduced TNF-induced NF-kB activity to levels comparable to
control (Figure 2d). Similar decrease in TNFa-induced NF-kB
luciferase activity was observed in cells transfected with
CK2a/b siRNAs (Figure 2f), conﬁrming the involvement of
CK2 in TNFa-induced aberrant NF-kB activation.
CK2-Is increases p53 expression in glioma cells. As
TNFa-activated NF-kB represses p53 transcriptional activity
and vice versa,
15 and as CK2-Is decreased TNFa-induced
NF-kB activation, we determined p53 status in CK2-I- and
TNFa-treated cells. A dramatic increase in p53 levels
accompanied with an increase in phosphorylation (Ser-15)
and acetylation (Lys373, 382) of p53 was observed upon
treatment with CK2-Is either alone or in the presence of
TNFa (Figure 3a). This increase was greater in p53 wild-type
(U87MG and A172) cells as compared with the slight
increase observed in p53 mutant (T98G) cells. Though
A172 is known to be a p53 mutant cell line,
24 sequencing of
DNA-binding region of p53 suggested it to be p53 wild type
for DNA-binding domain. p53 status in the glioma cell lines
was conﬁrmed by sequencing (Supplementary Table 1).
CK2 inhibition increases DNA-binding ability and
transcriptional activity of wild-type p53. Further, we
went on to investigate the effect of CK2-I-mediated
increase in p53 phosphorylation and acetylation on its
functional activity. Although CK2-Is increased DNA-binding
ability of p53 in U87MG and A172 by B 2–4-fold either alone
or in combination with TNFa, it had no signiﬁcant effect on
the binding ability of mutant p53 in T98G cells (Figure 3b).
This suggested that CK2 inhibition restores the function of
wild-type p53 independent of TNFa. Similarly, although a
B2–3-fold increase in p53 transcriptional activity was
observed in CK2-I-treated U87MG and A172 cells, its
activity remained unaltered in T98G cells (Figure 3c). This
CK2-I-induced increase in p53 DNA-binding ability and
transcriptional activity in U87MG and A172 cells was
signiﬁcantly reduced in the presence of p53 inhibitor,
Piﬁthrin-a (Figures 3b and c). The relevance of CK2 in the
activation of p53 function was further conﬁrmed in U87MG
and A172 cells, where siRNA-mediated knockdown of
CK2a/b increased p53 transcriptional activity (Figure 3d).
CK2-I-mediated increased p53 activity reduces glioma
cells viability. To establish the functional signiﬁcance of this
increased p53 levels, we determined the viability of CK2-I-
treated glioma cells in the presence of TNFa, p53 inhibitor
Piﬁthrin-a or both. The 50% decrease in cell viability
observed in U87MG and A172 upon treatment with TNFa
and DRB was signiﬁcantly reduced to B25% when TNFa and
CK2-I treatment was supplemented with Piﬁthrin-a
(Figure 3e). Similar results were obtained with Apigenin
also. This ability of Piﬁthrin-a to reverse TNFa and CK2-I-
mediated decrease in cell viability indicated the involvement
of p53 in CK2-I-induced cell death in p53 wild-type glioma
cells. However, ability of Piﬁthrin-a to reverse TNFa- and
CK2-I-mediated cell death in p53 mutant T98G cells was not
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Cell Death and Diseasesigniﬁcant (Figure 3e). Similarly, siRNA-mediated p53
knockdown was able to rescue CK2-I-induced cell death
both in the presence and absence of TNFa in p53 wild-type
glioma cells only (Figure 3f). These results conﬁrm the
involvement of p53 in CK2-I-mediated glioma cell death.
p53 null cells are resistant to CK2-I-induced
apoptosis. To conﬁrm the involvement of CK2-I-induced
p53 activation in inducing apoptosis, the effect of CK2-I on
the viability of p53 null cells H1229 and SaOS2 was
investigated. Both the p53 null cell lines were resistant to
Figure 2 CK2 inhibitors abrogate TNFa-induced NF-kB activation. (a) Fas and FADD expression in glioma cells treated with either TNFa or CK2-I or both for 24h as
demonstratedbywesternblot.Arepresentativeblotisshownfromthreeindependentexperimentswithidenticalresults.Blotswerereprobedforb-actintoestablishequivalent
loading. (b) Caspase-8 activity in glioma cells treated with CK2-Is or TNFa or both for 24h, as determined by the caspase-8 activity assay kit. (c) The graph represents the
viable cells, percentage of control, observed when glioma cells were treated with different combinations of TNFa, CK2-Is and caspase-8 inhibitor, as determined by MTS
assay.(d)Thelevelsof NF-kB, pIkKa/bandIkBaingliomacells,treatedwitheitherTNFaorCK2-Isorboth,asdemonstratedbywesternblot.Arepresentativeblot isshown
from three independent experiments with identical results. Blots were reprobed for b-actin and c23 to establish equivalent loading. (e) DRB and Apigenin decreases TNFa-
mediated NF-kB activation in glioma cells. The graph representsfold changein NF-kB luciferaseactivity over control, in cells treated with TNFa in the presenceand absence
of CK2-Is. (f) siRNA-mediated knockdown of CK2a/b decreases TNFa-induced NF-kB activation in glioma cells. Values in (b, c, e and f) represent the mean ±S.E.M. from
three independent experiments. *Denotes signiﬁcant change from control (Po0.05),
#denotes signiﬁcant change from TNFa. T, D and A denote TNFa, DRB and Apigenin,
respectively
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Cell Death and DiseaseCK2-I-induced apoptosis, as treatment with DRB and
Apigenin failed to induce apoptosis in both these cells.
However, CK2-I-mediated sensitization of p53 null cells to
TNFa could have resulted from downregulation of NF-kB
activity (Figure 3g).
CK2-Is increase expression of p53 target genes
associated with cell cycle regulation and
apoptosis. We next investigated whether activation of p53
function induces genes that promote cell cycle arrest
(p21and GADD45b) and apoptosis (Noxa). Although TNFa
Figure 3 CK2 inhibition triggers p53 expression and activation to induce glioma cell death. (a) Western blot indicated phosphorylated, acetylated and total p53 levels in
cells treated with CK2-Is in the presence and absence of TNFa. A representative blot is shown from three independent experiments with identical results. c23 was used as
loading control. (b) Increased binding of p53 to its DNA-binding sequence in cells treated with CK2-Is, either alone or in combination with TNFa, is abrogated by p53 inhibitor,
Piﬁthrin-a, Thegraphsrepresentrelativebinding activityof p53under differentconditions,as comparedwith untreatedcontrols. Valuesrepresentmeans±S.E.M.fromthree
individualexperiments.(c)CK2-I-mediatedincreaseinp53transcriptionalactivityisabrogateduponp53inhibition.Thegraphsrepresentfoldchangeinp53luciferasereporter
activityovercontrolincellstreatedwithdifferentcombinationsofCK2-Is,TNFaandPiﬁthrin-afor12h.(d)siRNA-mediatedknockdownofCK2a/binducesp53transcriptional
activityinp53wild-typebutnotinmutantcelllines.Thegraphrepresentsfoldchangeinp53luciferasereporteractivityoverNS-siRNA-transfectedcontrol.(e)CK2-I-mediated
sensitization of glioma cells to TNFa-induced death is reversed by Piﬁthrin-a and (f) p53 siRNA. The graphs represent percentage viable glioma cells treated with different
combinations of CK2-Is, TNFa and Piﬁthrin-a for 24h, as determined by MTS assay. (Inset) p53 siRNA abrogates CK2-I-induced p53 levels as determined by western blot
analysis. (g) CK2-I reduced viability of p53 null cells lines only in presence of TNFa. The graph represents percentage viable SAOS2 and H1299 cells treated with different
combinations of CK2-Is and TNFa. Values in (b–g) represent the means ± S.E.M. from three independent experiments. *Denotes signiﬁcant change from untreated control,
#denotes signiﬁcant change from CK2-I-treated cells either alone or in presence of TNFa (Po0.05)
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Cell Death and Diseasealone had no effect on p21, CK2-Is either alone
or in combination with TNFa elevated p21 expression
(Figure 4a). CK2-Is either alone or in combination with
TNFa increased mRNA levels of p53-induced pro-apoptotic
molecules GADD45b and Noxa (Figure 4a). This increase in
p21, Noxa and GADD45b level was downregulated by
Piﬁthrin-a (Figures 4a and b). No change in Noxa and
GADD45b levels was observed in cells treated with TNFa
alone (Figure 4b).
As changes in p21 expression indicated alteration in cell
cycle progression, we performed FACS analysis to determine
the cell cycle proﬁle of glioma cells treated with different
combination of CK2-Is, TNFa and Piﬁthrina. Although TNFa
had no signiﬁcant effect on cell cycle progression, treatment
with CK2-I induced G2/M arrest both in the presence and
absenceofTNFa(Figure4b).A5.4,5.8,15.3and14.3%,cells
at G2/M phase was observed in control, TNFa, Apigenin,
TNFa and Apigenin-treated A172 cells, respectively. Treat-
ment with Piﬁthrin-a reversed CK2-I-induced cell cycle arrest
(Figure 4c). Similar results were obtained in U87 cells also
(data not shown).
CK2-Is induces telomere shortening and senescence in
a p53-dependent manner. Activation of p53 leads to
telomere shortening, and repression of human telomerase
reverse transcriptase (hTERT) activity by p53 is mediated by
p21.
25 As p53 and p21 levels were elevated in CK2-I-treated
p53 wild-type cells, we determined hTERT activity in cells
treated with CK2-Is or TNFa or both. Although CK2-Is
decreased hTERT activity, this decrease was greater in the
presence of TNFa. Importantly, CK2-I mediated reduction in
hTERT activity was p53-dependent as the hTERT activity was
reversed signiﬁcantly in the presence of Piﬁthrin-a (Figure 5a).
As activation of p53-p21 pathway also acts as a major
mediator of cellular senescence induced by CK2 inhibition,
26
we determined b-galactosidase activity in CK2-I-treated
glioma cells. The increase in senescence-positive cells
observed in cells treated with CK2-I (Figure 5b) both in the
presence and absence of TNFa (Figure 5b), was abrogated in
the presence of Piﬁthrin-a.
CK2-I-mediated abrogation of NF-jB and increase in
p53 activation are independent events. Given that
Figure 4 CK2 inhibitor affects p53 target genes associated with cell cycle regulation and apoptosis. (a) CK2-I increases p21 expression in a p53-dependent manner.
Representative blot is shown from three independent experiments with identical results. Blots were re-probed with c23 to establish equivalent loading. (b) CK2-I increases
mRNAlevels of pro-apoptotic moleculesNoxaandGADD45b ina p53-dependent manner.TotalRNAwas isolatedfromcells treatedwith differentcombinations of TNFaand
CK2-I,andthemRNAlevelsforNoxa,GADD45bandconstitutiveenzymeGAPDHweredeterminedbyRT-PCR.(c)Piﬁthrin-areversesCK2-I-mediatedG2/Mphasearrestin
A172 cells. FACS analysis was performed on A172 cells treated with different combinations of TNFa, CK2-Is and Piﬁthrin-a. Inset indicates percentage of cells in G1, S and
G2/M phase of the cell cycle. C, T, Pf and A denote control, TNFa, Piﬁthrin-a and Apigenin, respectively
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Cell Death and DiseaseTNFa-activated NF-kB represses p53 transcriptional activity
and vice versa,
15 we investigated whether elevated p53
levels could have resulted in decreased NF-kB activation in
cells treated with a combination of TNFa and CK2-Is.
However, the ability of CK2-Is to downregulate TNFa-
induced NF-kB transcriptional activity was unaffected by
Piﬁthrin-a (Figure 5c). Thus, p53 activation and NF-kB
downregulation in CK2-I- and TNFa-treated cells are two
independent events.
CK2-Is differentially regulates expression of genes
associated with apoptosis in TNFa-treated p53 wild-type
and mutant glioma cells. To further establish which
apoptosis-related genes were altered upon treatment with
CK2 inhibitor, we performed a quantitative real-time PCR
(qRT-PCR)-based apoptotic gene array analysis. We
observed distinct patterns of gene expression in cells
treated with either TNFa or Apigenin or both in p53 wild-
type (A172) and mutant (T98G) glioma cells. In p53 wild-type
A172 glioma cells, among the 84 genes tested, transcript
levels of 20 genes were increased upon TNFa treatment
and their increased levels were abrogated signiﬁcantly with
CK2-Is (Table 1a). Most of these anti-apoptotic genes are
known to be regulated in TNFa- and NF-kB-dependent
Figure 5 CK2 inhibition-induced p53 activation decreases telomerase activity and induces senescence but has no effect on NF-kB activity. (a) CK2-Is decrease
telomeraseactivity in glioma cells in a p53-dependentmanner. Glioma cells were treatedwith TNFa in the presenceor absence of CK2-Is and/or Piﬁthrin-a; and TeloTAGGG
Telomerase PCR ELISA was performed. Values represent the means±S.E.M. from three independent experiments. (b) CK2-I-induced senescence in glioma cells is p53-
dependent as evident from senescence-speciﬁc b-gal staining. Images were taken at 20  magniﬁcation. The graph represents fold increase in b-gal-positive cells upon
treatmentwithdifferentcombinationsofApigenin,TNFaandPiﬁthrin-a.(c)Piﬁthrin-adoesnotaffecttheabilityofDRBtoabrogateTNFa-inducedNF-kBactivation.Thegraph
represents fold changeinNF-kB luciferaseactivityover control,in cellstreatedwith differentcombinationsof TNFa,DRB andPiﬁthrin-a. Valuesin (a–c)representthemeans
± S.E.M. from three independent experiments. *Denotes signiﬁcant change from control (Po0.05),
#denotes signiﬁcant change from CK2-I-treated cells (Po0.05)
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Cell Death and Diseasemanner (TNFRSF9, TNFSF10, BIRC3, CD40, TNFRSF11B,
RIPK2, BCL2L11, BID, BIK, XIAP, BNIP3, NOD1, CARD8,
TNFRSF1A, CD70, TRADD, TRAF2, TRAF3, BCL2 and
BCLAF1). Moreover, 10 genes (BCL2L1, BCL2L10,
PYCARD, APAF1, GADD45A, CIDEA, TNFRSF10A,
CASP10, CASP14 and CASP5) were found to be
upregulated by CK2-I independent of TNFa (Table 1a).
Several of these genes were found to be p53-dependent pro-
apoptotic factors. This indicated the importance of CK2-I-
induced p53 in regulating the pro-apoptotic response.
On the other hand, in p53 mutant T98G cell lines, transcript
levels of 10 TNFa and NF-kB target genes (BIRC3,
TNFRSF9, RIPK2, BCL2A1, PYCARD, CFLAR, TRADD,
TRAF2, TRAF3 and CARD6) were increased upon TNFa
treatment and their increased levels were brought down
signiﬁcantly by CK2-I. Moreover, levels of four pro-apoptotic
genes (CASP10, CASP14, CASP5 and CIDEA) were
upregulated upon CK2 inhibition. Similarly, transcript levels
of four genes (XIAP, BIRC6, NOL3 and TRAF4) were
downregulatedsigniﬁcantlyuponCK2-Itreatmenteitheralone
or in presence of TNFa. All of them are known apoptotic
inhibitors (Table 1b).
CK2-I increases the stability of p53 by decreasing its
ubiquitination. As CK2-I induced p53 expression without
effecting its transcript level (Table 1), we investigated
whether CK2-I-mediated increase in p53 level was the
consequence of increased stability of the p53 protein. The
role of CK2 on p53 stability was determined by treating
glioma cells with protein synthesis inhibitor, Cycloheximide
(CHX), in the presence and absence of CK2-I. Although
expression of p53 decreased rapidly after incubation with
CHX in untreated cells, treatment with Apigenin prevented
such degradation (Figure 6a). This suggested increased
stabilization of p53 upon CK2 inhibition.
Decreased MDM2–p53 association upon CK2 inhibition
leads to p53 stabilization. Ubiquitin ligase MDM2
negatively regulates p53 stability by promoting its ubiquitin-
mediated degradation
27 and CK2 is known to regulate p53
turnover through MDM2.
28 We therefore investigated
whether CK2-mediated stabilization of p53 is MDM2-
dependent. As no change in MDM2 levels was observed
upon treatment of glioma cells with CK2-I, both in the
presence and absence of TNFa (data not shown), we
investigated whether CK2-Is alter the association of p53
with MDM2. Association of p53 with MDM2 decreased upon
CK2-I treatment (Figure 6b). It is possible that decreased
MDM2–p53 association prevents rapid degradation of p53,
leading to its accumulation in CK2-I-treated glioma cells. This
decreased MDM2–p53 interaction was concomitant with
decrease in p53 ubiquitination, suggesting that CK2-I
increases p53 levels by preventing ubiquitin-mediated p53
degradation (Figure 6b).
CK2 regulates SIRT1 activity in glioma cells. As CK2
regulate p53 activity through SIRT1-dependent deacetylation
18
and as we have observed increased p53 acetylation upon
CK2-I treatment, we determined SIRT1 activity in cells
treated with CK2-Is both in the presence and absence of
TNFa.AB30–40% decrease in SIRT1 activity was observed
in CK2-I-treated cells independent of TNFa (Figure 7a).
Table 1 (a) A172 fold change over control; (b) T98G fold change over control
TNFl TNF+Api Apigenin
(a)
TNFRSF9 33.2205 2.5758  1.6189
TNFSF10 16.9592  4.6428  5.8159
BIRC3 23.007 7.9723 1.5746
CD40 14.1625 6.8924 2.6945
TNFRSF11B 4.9383  5.6178  6.8448
RIPK2 2.0907  1.7839  3.0001
BCL2L11 1.9507  3.3058  3.5186
BIK 3.2021 1.7171 1.366
XIAP 1.3186  1.7777  2.3376
BNIP3 1.5147  1.7593  1.8987
NOD1 1.9372 1.1447  1.0755
CARD8 1.433  1.834  2.7132
TNFRSF1A 1.428  4.3169  3.4702
CD70 1.8519  1.6702  2.8779
TRADD 1.6748  2.4284  3.5925
TRAF2 2.7397 1.3996  1.5746
TRAF3 1.9106 1.3472  1.257
BCL2 1.4835  1.3472  3.1821
BCLAF1 1.458  2.0491  1.9319
BCL2L1 1.1321 10.7034 4.976
BCL2L10 1.8013 14.4701 11.2356
PYCARD 1.9711 10.2319 5.3517
APAF1 1.1559 6.8211 5.5022
GADD45A 2.1947 12.3805 8.6939
CIDEA 3.093 10.8528 6.0002
TNFRSF10A 3.1799 14.1232 10.2674
CASP10 1.7459 6.9886 5.5597
CASP14 3.4319 15.455 10.6664
CASP5 1.7279 5.2964 5.5597
BIRC6 1.1761  6.2333  4.8736
CRADD 1.2008  3.1167  3.2603
CARD6 1.1966  4.7076  5.716
BAG4 1.1088  2.0139  2.6117
DAPK1  1.17  2.6299  2.7321
TP53 2.157  1.25  1.48
(b)
BIRC3 22.28 3.2 1.04
TNFRSF9 33.54 3.71 1.1
RIPK2 6.91 2.2 1.52
BCL2A1 2.88 1.36 1.16
PYCARD 2.08  1.26  1.65
CFLAR 2.05  1.85  1.3
TRADD 1.88  2.33  1.49
TRAF2 1.85  1.29 1.46
TRAF3 2.41 1.39 1.45
CARD6 1.62  1.65  1.15
XIAP 1.39  1.75  1.19
BIRC6 1.21  2.01  1.22
NOL3 1.06  3.68  1.15
TRAF4 1.16  2.07  1.58
CASP10 2.36 7.36 4.77
CASP14  1.16 13.93 14.87
CASP5  1.67 5.43 9.67
CIDEA 1.3 2.66 6.34
TP53 1.2 1.01 1.25
Abbreviation: TNF, tumor necrosis factor. Quantitative real-time PCR to
evaluate the relative transcript levels of a panel of 84 genes associated with
apoptosis in cells treated with different combinations of CK2 inhibitor and TNFa.
Gene expression proﬁling of mRNA isolated from glioma cells - A172 (Table 1a)
and T98G (Table 1b), treated with TNFa in the presence and absence of
Apigenin, was analyzed by quantitative PCR for genes involved in apoptotic
pathways. Expressions of several genes affected by the treatments are shown.
Table represents the average data from two independent experiments
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Cell Death and DiseaseElevated SIRT1 levels in glioma samples. As SIRT1 is
associated with tumorigenesis and resistant to radio- and
chemotherapy,
29 we determined its expression levels in
GBM tumor samples as compared with adjacent normal
tissue. We report for the ﬁrst time an elevated expression of
SIRT1 in GBM tumor samples as compared with the
surrounding non-neoplastic tissue, as demonstrated by IHC
and western blotting (Figure 7b).
Role of SIRT1 in CK2-I-induced p53-dependent glioma
cell apoptosis. In order to conﬁrm the involvement of CK2-
I-induced decrease in SIRT1 activity on glioma cell proliferation,
we determined viability of cells over-expressing WT-SIRT1 in
the presence and absence of CK2-Is. Over-expression of
SIRT1 signiﬁcantly prevented CK2-I-induced apoptosis both in
the presence and absence of TNFa (Figure 7c).
As SIRT1 regulates p53,
18 we next investigated the role of
SIRT1 in CK2-I-induced p53 transcription activity in cells
transfected with WT-SIRT1 in the presence and absence of
CK2-Is and TNFa. Increase in p53 transcriptional activity
observed upon treatment with CK2-I was abrogated upon
SIRT1 over-expression (Figure 7d). These results clearly
suggested the involvement of SIRT1 in the regulation of
CK2-I-induced p53 activation and subsequent decrease in
glioma cells viability.
Discussion
Casein kinase-2 is reported to have a role in overcoming
resistance of glioma cells towards radiation therapy.
30 More-
over, CK2-Is target NF-kB signaling
11 and as inactivation of
NF-kB sensitizes glioma cells to TNFa-induced apoptotic cell
death.
2,3 These ﬁndings compelled us to investigate whether
inhibition of CK2 could sensitize glioma cells to TNFa-induced
apoptosis. We report for the ﬁrst time an elevated expression
ofCK2inGBMtumorsascomparedwiththesurroundingnon-
neoplastic tissue. Our studies indicate that CK2-Is DRB and
Apigenin as well as CK2 siRNA sensitizes glioma cells to
TNFa-induced cell death. Though CK2 inhibitor trigger
apoptosis through FADD and caspase-8,
22 neither DRB nor
Apigenin increased Fas or FADD expression or utilized
caspase-8-mediated signaling to induce glioma cell death.
CK2 is known to regulate TNFa-dependent NF-kB activity,
31
and similarly in glioma cells, treatment with both DRB and
Apigenin abrogated TNFa-induced NF-kB activation.
CK2 inhibition in glioma cells triggered activity of wild-type
p53asevidencedbyincreasedp53levels, itsphosphorylation
and acetylation, DNA-binding ability and transcriptional
activation. However, CK2-I failed to affect the functionality of
mutant p53. It is known that receptor-interacting protein 1,
which is a critical component of NF-kB signaling, inhibits p53
Figure 6 CK2 inhibition leads to p53 protein stabilization. (a) CK2-I prevents degradation of p53. Glioma cells, either untreated or treated with Apigenin for 12h were
further treated with CHX for the indicated times. Western blot analysis was performed to determine p53 levels in the lysates. Representative blot is shown from three
independent experiments withidenticalresults.Blotswerereprobedfor GAPDHto establishequivalentloading.Densitometricanalysisshowsp53levelsuponCHXtreatment
in the presence and absence of Apigenin. (b) CK2-I decreases MDM2–p53 interaction and p53 ubiquitination in glioma cells. Lysates from cells treated with Apigenin were
immunoprecipitatedwith p53andprobedwith antibodiesagainstMDM2andubiquitin.IgG levelsare showntoestablishequivalentloading.Representativeblotisshownfrom
two independent experiments with identical results. *Denotes signiﬁcant change from control (Po0.05)
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Cell Death and Diseasefunction through NF-kB activation in glioblastoma.
32 It is
possible that although CK2-I-induced p53 activation triggered
cell death, it was the ability of CK2-Is to inhibit TNFa-induced
NF-kB activation that lead to synergistically enhanced cell
death in the presence of TNFa. Restoration of p53 function by
CK2-Is was accompanied by elevated expression of p53
target genes p21, NOXA and GADD45b that are associated
with apoptosis and cell cycle arrest. The results of gene
expression proﬁling suggested differential responsiveness of
p53 wild-type and mutant cells to CK2 inhibition, in terms of
theexpressionofgenes thatareknownp53targets,aswellas
those relevant for the activation of caspases and induction of
TNFa-mediated apoptosis. Gene proﬁling array also con-
ﬁrmed our observation that CK2 inhibition does not involve
caspase-8, as no change in its levels was observed in cells
treated with TNFa in the presence of Apigenin. Though CK2-I
had no effect on the expression of p53 mRNA levels as
demonstrated by the PCR array, it increased the stability of
p53 protein by decreasing its ubiquitination and interaction
with MDM2 to prevent subsequent degradation.
The decrease in SIRT-1 activity in glioma cells upon CK2
inhibition was associated with p53 activation, as over-
expression of SIRT1 prevented CK2-I-mediated increase in
p53 transcriptional activation. This was not surprising as CK2
regulates p53 activity directly and indirectly through SIRT-1.
19
Importantly, SIRT1 over-expression rescued glioma cells
from CK2-I-induced apoptosis. An increase in senescence
was also observed in CK2-I-treated cells. It is possible that
decreaseinSIRT1activityleadtosenescence,asinductionof
senescence-like growth arrest in human breast and lung
cancercellsbySirtinol–aspeciﬁcinhibitorforSIRT1hasbeen
reported.
33 Given that both CK2 and SIRT1 are elevated in
Figure 7 CK2 inhibitor-mediated downregulation of SIRT1 activity regulates p53. (a) CK2-Is decrease SIRT1 activity in glioma cells both in the presence and absence of
TNFa. Glioma cells were treated with TNFa in the presence or absence of DRB/Api and subsequently SIRT1 activity was determined. Values represent the means±S.E.M.
from three independent experiments. (b) SIRT1 immuno-localization in glioma tumor samples as revealed by IHC and western blot analysis. Cryosections of glioma and
adjacent normal tissues were immunostained for SIRT1 as described in Materials and Methods. Images were taken at 40  magniﬁcation. Western blot analysis also
demonstrated elevated SIRT1 levels in GBM tumor as compared with surrounding non-neoplastic tissue. The ﬁgure shows blots from ﬁve independent tumor samples with
identical results. (c) CK2-I-mediated decrease in SIRT1 activity regulates glioma cell viability. The viability of glioma cells transfected with SIRT1 over-expression vector and
treatedwithApigeninorTNFaorbothfor24h,was determined byMTSassay.Thegraphrepresentspercentageviablecellsofcontrol.InsetshowstheoverexpressedSIRT1
levelsasdeterminedbyimmunoblotting.(d)CK2-I-mediatedincreaseinp53transcriptionalactivityisabrogateduponSIRT1over-expression.Gliomacellsco-transfectedwith
SIRT1 over-expression vector and p53 luciferase reporter constructs were treated with Apigenin or TNFa or both and reporter assay was performed to determine p53
transcriptional activity. The graph represents fold change in p53 luciferase reporter activity over control. Values in (a, c and d) represent the means±S.E.M. from three
independent experiments. *Denotes signiﬁcant change from control (Po0.05),
#denotes signiﬁcant decrease from mock-transfected CK2-I-treated cells (Po0.05)
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Cell Death and DiseaseGBM and their downregulation is concomitant with apoptosis
and senescence, our study suggests that targeting CK2-
SIRT1 nexus might shed light on how CK2 regulates glioma
progression.
Our studies indicate that CK2 inhibitor (i) sensitizes glioma
cells to TNFa-induced apoptosis in an caspase-8-indepen-
dent manner (ii) decreases TNFa-induced NF-kB activation
(iii) reactivates wild-type p53 function (iv) inhibits SIRT1
activity (v) inhibits telomerase activity and (vi) induces
senescence (Figure 8). Taken together, CK2-I sensitizes
both p53 wild-type and mutant glioma cells to TNFa-induced
apoptosis. Depending on the p53 status, this is achieved by
CK2-Is either through abrogation of NF-kB activation and/or
rescue of wild-type p53 function. Importantly, this ability of
CK2-I to induce glioma cell death irrespective of p53 status
may be of clinical signiﬁcance for the treatment of glioma,
wherep53 mutation is consideredcritical for itsprogression.
16
Although activation of p53 triggers apoptosis, stimulation of
NF-kB promotes resistance to apoptosis. Interestingly, CK2-
Is co-ordinate these two opposing events to overcome TNFa-
induced resistance to apoptosis. As induction of both
senescence and apoptosis in human cancer cells has been
reported,
34 the ability of CK2-I to induce both these events to
reduce cell viability warrants further investigation of CK2 as a
potential anti-glioma target.
Materials and Methods
Processing of tissue and IHC. IHC was performed on tissue samples
collected from patients with histologically conﬁrmed GBM (n¼19) to determine
CK2 and SIRT1 expression as described.
35 Non-neoplastic brain tissue (n¼7)
obtained from margins of the tumors whenever possible was used as control.
Samples were obtained as per the guidelines of Institutional Human Ethics
Committee of NBRC.
Cellcultureandtreatment. GlioblastomacelllinesA172,U87MGandT98G
were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA)
andculturedinDMEMsupplementedwith10%fetalbovineserum.Onattainingsemi-
conﬂuence,cells wereswitched toserum-freemedia (SFM)and after12h,cells were
treated with different concentration of DRB or Apigenin (in Dimethyl sulphoxide,
DMSO) or Piﬁthrin-a in the presence or absence of TNFa (50ng/ml) in SFM for 24h.
DMSO-treated cells were used as controls. All reagents were purchased from Sigma
unless otherwise stated. The p53 null cell lines H1229 and SaOS2 were a kind gift
from Dr. Sanjeev Das, National institute of Immunology, India.
Determination of cell viability. Viability of cells treated with different
combinations of TNFa, CK2-Is and Piﬁthrin-a for 24h in 96-well plates was
assessed using the MTS assay (Promega, Madison, WI, USA) as described.
36
Values were expressed as a percentage relative to those obtained in controls.
Western blot and immunoprecipitation. Protein was isolated from
whole-celllysatesandnuclearextractsfromcellstreatedwithdifferentcombinations
of TNFa, CK2-Is and Piﬁthrin-a and western blot was performed as described.
37
The following antibodies were used: p21 (BD Biosciences, San Diego, CA, USA),
pp53ser15, MDM2,SIRT1 (Abcam, Cambridge, UK), acetylatedp53 lys373,lys382
(Millipore, Temecula, CA, USA), pIKKa/b (Ser176/180), IkBa, p53 (Cell Signaling,
Danvers, MA, USA), Ub (Dako, Glostrup, Denmark) CK2a, Fas and FADD, p53,
p65, c23, GAPDH. Antibodies were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA) unless otherwise mentioned. Secondary antibodies were
purchased from Vector Laboratories Inc. (Burlingame, CA, USA). The blots were
stripped and re-probed with anti-b-actin (Sigma, St. Louis, MO, USA) to determine
equivalent loading as described.
37 Immunoprecipitation was performed with p53
antibody to determine the association of p53-MDM2 as described.
38
Assay of caspase-3 and 8 activities. The Colorimetric Assay kits for
caspases-3 and 8 (Sigma) were used to determine the enzymatic activity of
caspases in cells treated with different combinations of TNFa and CK2-Is as
described.
39
Luciferasereportergeneassay. Reporterassayincellstransfectedwithp53
or NF-kB luciferase or WT SIRT1 constructs, and treated with different
combinations of TNFa, CK2-Is and Piﬁthrin-a was performed as described.
37 The
p53luciferaseandSIRT1constructswereobtainedfromAddgene(Cambridge,MA,
USA) and NF-kB luciferase construct obtained from Clontech (Madison, WI, USA).
siRNA transfection. Before 18h of transfection, 3 10
4 cells were seeded
onto 24-well plates in medium without antibiotics and transfection with 50nmol/l
duplex CK2a, CK2b, p53 or non-speciﬁc siRNA (Thermo Fischer Scientiﬁc,
Lafayette, CO, USA) was carried using Lipofectamine RNAi Max reagent (Life
Technologies-Invitrogen, Carlsbad, CA, USA) as described.
40
p53DNA-bindingassay. DNA-bindingactivityofp53wasmeasuredwiththe
DuoSet IC (IntraCellular) Assay Development System (R&D Systems, Minneapolis,
MN, USA) according to manufacturer’s instructions.
Telomerase activity. Telomerase activity of cells treated with TNFa in the
presence and absence of CK2-Is and Piﬁthrin-a was determined using
the TeloTAGGG Telomerase PCR ELISA Plus kit (Roche Diagnostics,
Mannheim, Germany) as described.
39
Flow cytometric analysis of DNA content. FACS analysis was
performed to determine the effect of TNFa or Apigenin or both in the presence
and absence of Piﬁthrin a on cell cycle progression of glioma cells, using Cell Quest
program on FACS Calibur (Becton Dickinson, San Diego, CA, USA) as described.
5
Results were analyzed using Cell Quest pro software (Becton Dickinson).
Senescence-associated b-gal staining. Cells treated with CK2-Is either
alone or in presence of TNFa and/or Piﬁthrin were stained with the senescence-
associated b-galactosidase (SA-b-gal) staining solution (Sigma) as per the
manufacturer’s instructions. The numbers of blue-stained (SA-b-gal-positive) cells
and total cells were counted microscopically and percentage of SA-b-gal-positive
cells was calculated.
SIRT1 activity assay. Deacetylase activity of SIRT1 was measured with
SIRT1 activity assay kit from Calbiochem (Merck KGaA, Darmstadt, Germany)
according to manufacturer’s instructions.
Figure 8 Proposed model demonstrating the role of CK2 in glioma cell
apoptosis and resistance to therapy. CK2 inhibition induces glioma cell death via
activation of p53 through SIRT1 inhibition and sensitizes glioma cell to TNFa via
downregulation of TNFa-induced NF-kB activity
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Cell Death and DiseaseRT-PCR and human apoptosis qRT-PCR array. RT-PCR analyses for
NOXA and GADD45b expression in cells treated with different combinations of
TNFa and CK2-Is was performed as described.
37 PCR primers for NOXA and
GADD45b are listed in Supplementary Table 2. qRT-PCR was performed using an
apoptosis PCR Array containing 84 apoptosis-related genes (SuperArray
Biosciences, Frederick, MD, USA) as per manufacturer’s instruction. Brieﬂy, total
RNA samples from TNFa and Apigenin-treated A172 and T98G glioma cells were
isolated using RNeasy Mini Kit (Qiagen, Hilden, Germany). An equal amount of
RNA (2mg) was used for reverse transcription using RT2 First Strand Kit
(SuperArray Biosciences). PCR reactions were done using the RT2 proﬁler PCR
array PAHS-012 (Human Apoptosis PCR Array) on the ABI 7500 using RT2 Real-
time SYBR Green PCR master mix PA-012. The total volume of the PCR reaction
was 25ml. The thermocycler parameters were 951C for 10min, followed by 40
cyclesof 951C for 15sand 601C for 1min.Five housekeeping geneswere included
on the array (B2M, HPRT1, RPL13A, GAPDH, and ACTB) to normalize the
transcript levels. Results were analyzed as per user manual guidelines using
integrated web-based software package for the PCR Array System (SuperArray
Biosciences RT2 Proﬁler PCR Array Human Apoptosis PAHS-012–A-12).
Statistical analysis. All comparisons between groups were performed using
two-tailed paired student’s t-test. All P-values o0.05 were taken as signiﬁcant.
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